EOLS - Evolus, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.0400
-0.0800 (-1.94%)
At close: 4:00PM EDT

4.0400 0.00 (0.00%)
After hours: 4:15PM EDT

Stock chart is not supported by your current browser
Previous Close4.1200
Open4.1500
Bid4.0000 x 1000
Ask4.0200 x 800
Day's Range3.8900 - 4.2600
52 Week Range3.1150 - 29.4000
Volume399,906
Avg. Volume776,627
Market Cap136.261M
Beta (5Y Monthly)3.93
PE Ratio (TTM)N/A
EPS (TTM)-3.1880
Earnings DateFeb 24, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.44
  • GlobeNewswire

    Evolus Provides Update on International Trade Commission (ITC) Case

    The Judge assigned to the ITC case is not obligated to accept a staff attorney’s position on the facts, and it’s fairly common for the Judge and the staff attorney to disagree on substantive matters. Evolus and Daewoong remain confident in the strength of our intellectual property and will continue to vigorously defend it through the entirety of the ITC process. In addition, numerous claims have been made in the Korean press regarding settlement discussions related to the ITC proceedings.

  • GlobeNewswire

    Evolus to Participate in Barclays 2020 Global Healthcare Conference

    NEWPORT BEACH, Calif., March 03, 2020 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.

  • Implied Volatility Surging for Evolus (EOLS) Stock Options
    Zacks

    Implied Volatility Surging for Evolus (EOLS) Stock Options

    Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.

  • GlobeNewswire

    Evolus Reports Fourth Quarter and Full Year 2019 Results and Provides Business Update

    Q4 2019 Net Revenue $19.5 Million, Up from $13.2 Million in Q3 2019 Jeuveau® Achieved Number Three Unit Share Position in the U.S. in 20191 Launched Evolux™;.

  • ACCESSWIRE

    Evolus, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 25, 2020 / Evolus, Inc. (NASDAQ:EOLS) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 25, 2020 at 8:00 AM ...

  • GlobeNewswire

    Evolus to Participate in 9th Annual SVB Leerink Global Healthcare Conference

    NEWPORT BEACH, Calif., Feb. 13, 2020 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.

  • GlobeNewswire

    Evolus to Report Fourth Quarter and Full Year 2019 Financial Results and Provide a Business Update on Tuesday, February 25, 2020

    NEWPORT BEACH, Calif., Feb. 12, 2020 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.

  • 3 Healthcare Stocks That Offer a Compelling Buying Opportunity
    TipRanks

    3 Healthcare Stocks That Offer a Compelling Buying Opportunity

    When shares fall, investor focus locks in. The first instinct, for some, is to avoid the name entirely after the investing alarm bells have been sounded. Sure, dropping share prices can indicate that there’s a deeper issue hampering the company such as weak fundamentals or headwinds that appear unbeatable. Having said that, this isn’t the case for every stock that has seen its share price take a hit.Wall Street pros remind investors that while not all beaten-down names are primed for a recovery, others offer investors a unique buying opportunity, with their current share prices reflecting an attractive entry point.So, how are investors supposed to know when it’s time to buy the dip? TipRanks' Stock Screener tool helped us zero in on 3 compelling stocks, specifically in the healthcare industry, by filtering our search results by sector, analyst consensus and price target upside. While these names have taken a beating, each has generated substantial bullish sentiment from the analysts and boasts massive upside potential from current levels. Let’s dive right in.Sientra, Inc. (SIEN)First up, we have Sientra, a company that is best known for producing implants and other products for breast augmentation or reconstruction procedures. While the healthcare name has started off 2020 down 25%, Wall Street analysts see better days on the horizon.The recent weakness actually follows a relatively solid preliminary fourth quarter revenue announcement. On January 13, the company told investors that miraDry’s better-than-expected performance drove a modest revenue beat. However, the breast segment missed the mark and there are still some concerns regarding its balance sheet as its cost restructuring efforts won't generate cash flow benefits until 2021.That being said, Leerink Partners analyst Richard Newitter points out that the breast segment still achieved 20%-plus growth, and his conversation with SIEN management actually implies that its breast implant business accelerated. Additionally, he stated that if one-time events are excluded, cash burn improved.As a result, he argues that the pullback is “too excessive.“ “We've seen SIEN's stock react unexplainably negative in the past to otherwise solid results (i.e., initially after a 2Q19 beat) only to recover shortly thereafter. We think this will prove to be one of those situations and reiterate our OP rating as we continue to believe SIEN's valuation discount is disconnected from an over 20% top-line growth profile,” he explained.With Newitter anticipating that its OPUS implant launch and miraDry sales growth will also help fuel a recovery, it makes sense that he still sides with the bulls. To this end, the five-star analyst reiterated an Outperform recommendation and $13 price target. Should this target be met, shares could be in for a 93% twelve-month gain. (To watch Newitter’s track record, click here)What does the rest of the Street think? Based on 100% Street support, or a total of 6 bullish calls assigned in the last three months, the consensus rating is a unanimous Strong Buy. The $13.20 average price target puts the upside potential above Newitter’s forecast at 96%. (See Hercules Capital’s stock analysis at TipRanks)ViewRay, Inc. (VRAY)ViewRay is focused on giving clinicians new and more effective ways to treat cancer using radiation. Its approach uses MRI-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. With this groundbreaking offering, why have shares dipped 25% year-to-date?The share price decline comes on the heels of its preliminary Q4 results. VRAY announced that it expects quarterly sales of $17 million, landing very close to the consensus estimate. However, new orders largely disappointed, with this figure coming in at $21 million. As this is down from $49 million in the prior-year quarter, it’s no wonder investors have been concerned. It also didn’t help that VRAY burned through about $3 million in cash.That isn’t to say investors should give up on the healthcare name. Piper Sandler’s Matthew O'Brien did acknowledge the result was unexpected “as momentum in the order book appeared to have been building with eight orders (three upgrades) last quarter.” However, he argues that the soft order figure is indicative of “standard lumpiness capital equipment sales”, which should improve in the coming quarters.“Although we do not expect this to be the last bump in the road, we remain highly confident in the utility of the MRIdian as the best technology to treat cancer patients, and we believe it will yield significant share-taking over the next couple of years,” O’Brien commented. He added, “We believe today’s dip represents a buying opportunity to investors willing to weather some quarterly volatility...”As recent investments from heavyweights Medtronic and Elekta boosted its capital, VRAY should be able to improve system install times as well as access potential hospital targets for the MRIdian system. Based on all of these factors, the five-star analyst maintained an Overweight rating and $6 price target. At this target, shares could soar 89% in the next twelve months. (To watch O’Brien’s track record, click here)Like O’Brien, other Wall Street analysts are staying on board. 6 Buys and a single Hold issued in the last three months add up to a Strong Buy analyst consensus. In addition, the $6.71 average price target implies 112% upside potential. (See ViewRay stock analysis on TipRanks)Evolus, Inc. (EOLS) Evolus is giving people a reason to smile, offering an FDA-approved injectable medicine to improve the appearance of frown lines. Despite shedding 19% of its value since the beginning of 2020, one analyst believes that EOLS will be able to turn investors’ frowns upside down.Marc Goodman of Leerink Partners wrote in a recent note that he suggests “aggressive buying of EOLS shares” after the stock’s tumble. Shares set off on a downward trajectory after it pre-announced its fourth quarter results. Total sales could land within the range of $18.5 million to $19.5 million, compared to the $16.1 million consensus estimate. In addition, the amount of purchasing accounts is expected to increase substantially from about 2,000 in the third quarter to almost 3,500 in the fourth quarter.“We are baffled by the weakness today and view as a great buying opportunity. In our view, commercial execution by this management team has been excellent so far and the sales ramp is very encouraging. From a ‘back of the envelope’ view we simplistically say that if this is just a $250 million peak sales product, these types of aesthetics assets trade for at least 5x sales, and thus that implies a valuation at least 3x where the stock currently trades,” Goodman noted.Even though the four-star analyst points out that investors have been worried about the lockup period for Alphaeon, which owns 26%, and the ITC litigation, he doesn’t think that either hampers its long-term growth prospects.Bearing this in mind, he kept his Outperform rating and $25 price target as is. This target conveys his confidence in Evolus’ ability to climb 154% higher in the twelve months ahead. (To watch Goodman’s track record, click here)Looking at the consensus breakdown, 6 Buys, 1 Hold and 1 Sell make the consensus rating a Moderate Buy. It should be noted, though, that the average price target of $26.88 indicates a whopping 173% potential twelve-month gain. (See Evolus stock analysis on TipRanks)

  • GlobeNewswire

    Positive Results from Phase III, Split-Face, Head-to-Head Study Comparing OnabotulinumtoxinA and PrabotulinumtoxinA in the Treatment of Crow’s Feet Lines Published in Dermatologic Surgery

    NEWPORT BEACH, Calif., Jan. 27, 2020 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.

  • GlobeNewswire

    Evolus Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Revenue

    Evolus, Inc. (EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced its preliminary unaudited revenues for the fourth quarter and full year ended December 31, 2019 and cash position at December 31, 2019. The preliminary unaudited results described in this press release are estimates only and are subject to revision until the company reports its full financial results for the fourth quarter and full year 2019. Cash, cash equivalents and short-term investments were $129.8 million at December 31, 2019.

  • Need To Know: Evolus, Inc. (NASDAQ:EOLS) Insiders Have Been Buying Shares
    Simply Wall St.

    Need To Know: Evolus, Inc. (NASDAQ:EOLS) Insiders Have Been Buying Shares

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...

  • Is Evolus, Inc. (EOLS) A Good Stock To Buy?
    Insider Monkey

    Is Evolus, Inc. (EOLS) A Good Stock To Buy?

    Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts, usually don't make them change their opinion towards a company. This time it may be different. During the fourth quarter of 2018 we observed increased volatility and a 20% drop in […]

  • GlobeNewswire

    Evolus to Participate in Stifel Healthcare Conference

    NEWPORT BEACH, Calif., Nov. 07, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.

  • What Kind Of Shareholder Owns Most Evolus, Inc. (NASDAQ:EOLS) Stock?
    Simply Wall St.

    What Kind Of Shareholder Owns Most Evolus, Inc. (NASDAQ:EOLS) Stock?

    The big shareholder groups in Evolus, Inc. (NASDAQ:EOLS) have power over the company. Institutions will often hold...

  • GlobeNewswire

    Evolus Announces Pricing of Public Offering of Common Stock

    Evolus, Inc. (EOLS) (“Evolus”) announced today the pricing of its public offering of 5,217,000 shares of its common stock at a public offering price of $13.00 per share, before underwriting discounts and commissions. Evolus is expected to receive net proceeds of approximately $63.5 million, after deducting underwriting discounts and commissions and estimated offering expenses. In addition, Evolus has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 782,550 shares at the public offering price, less the underwriting discounts and commissions.

  • GlobeNewswire

    Evolus Announces Proposed Public Offering of Common Stock

    Evolus, Inc. (EOLS) (“Evolus”) announced today that it has commenced a proposed underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. Evolus expects to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 15% of the shares of its common stock offered in the public offering. All of the shares in the offering are to be sold by Evolus.

  • GlobeNewswire

    Evolus Reports Third Quarter 2019 Financial Results and Provides Business Update

    Jeuveau® Generated $13.2 Million in U.S. Net Revenue in Q3 2019; up from $2.3 Million in Q2 2019 J.E.T. Enrolled Accounts Drove 90% of Q3 Revenue Jeuveau®.

  • Hedge Funds Have Never Been This Bullish On Evolus, Inc. (EOLS)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Evolus, Inc. (EOLS)

    While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, increasing oil prices and deteriorating expectations towards the resolution of the trade war with China, many smart money investors kept their cautious approach regarding the current bull run in the second quarter and hedging or reducing many of […]

  • GlobeNewswire

    Evolus to Report Third Quarter 2019 Financial Results and Provide a Business Update on Monday, November 4, 2019

    NEWPORT BEACH, Calif., Oct. 28, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.

  • GlobeNewswire

    Evolus and Clarion Medical Technologies Announce First Shipment of Nuceiva™ (prabotulinumtoxinA) to Customers in Canada

    Evolus, Inc. (EOLS) and Clarion Medical Technologies, a leading Canadian provider of medical and aesthetic equipment and consumables, today announced the first shipment of Nuceiva™ (prabotulinumtoxinA) in Canada. Nuceiva™ is a 900 kDa purified botulinum toxin type A formulation that is approved by Health Canada for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients

  • Allergan (AGN) Shareholders Approve Acquisition by AbbVie
    Zacks

    Allergan (AGN) Shareholders Approve Acquisition by AbbVie

    Allergan's (AGN) shareholders give green signal to its pending merger with AbbVie for a transaction value of nearly $63 billion.

  • GlobeNewswire

    Evolus Receives Approval for Nuceiva™ in the European Union

    Evolus, Inc. (EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that the European Commission (EC) has approved the marketing of Nuceiva™ (prabotulinumtoxinA). Similar to other neurotoxins marketed in Europe, Nuceiva™ is approved for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity of the facial lines has an important psychological impact in adults below 65 years of age.

  • Market Sentiment Around Loss-Making Evolus, Inc. (NASDAQ:EOLS)
    Simply Wall St.

    Market Sentiment Around Loss-Making Evolus, Inc. (NASDAQ:EOLS)

    Evolus, Inc.'s (NASDAQ:EOLS): Evolus, Inc., a performance beauty company, provides medical aesthetic products for...

  • GlobeNewswire

    Evolus will Participate in Cantor Global Healthcare Conference

    NEWPORT BEACH, Calif., Sept. 18, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.

  • GlobeNewswire

    Evolus Announces Successful Completion of the Jeuveau® Experience Treatment (J.E.T) Program

    Evolus, Inc. (EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the company has successfully completed the J.E.T. Program and achieved the number three unit share position for Jeuveau® in the United States. Visit us at: www.evolus.com.